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Abstract
Background: Conventional external beam radiotherapy is a standard procedure for treatment of spinal metastases.
In case of progression spinal cord tolerance limits further radiotherapy in pre-irradiated areas. Spinal stereotactic
radiotherapy is a non-invasive option to re-treat pre-irradiated patients. Nevertheless, spinal radiosurgery results in
relevant dose deposition within the myelon with potential toxicity. Aim of the study was to retrospectively analyse
the efficacy and feasibility for salvage radiosurgery of spinal metastases.
Methods: During a period of 4 years (2005-2009) 70 lesions in 54 patients were treated in 60 radiosurgery sessions
and retrospectively analysed. Clinical (pain, sensory and motor deficit) and radiological (CT/MRI) follow-up data
were collected prospectively after radiosurgery. Pain - as main symptom - was classified by the Visual Analogue
Scale (VAS) score. Every patient received single session radiosurgery after having been treated first-line with
conventionally fractionated radiotherapy. Kaplan-Meier method and life tables were used to analyse freedom from
local failure and overall survival.
Results: At a median follow-up of 14.5 months the actuarial rates of freedom from local failure at 6/12/18 months
were 93%, 88% and 85%, respectively. The median radiosurgery dose was 1 × 18 Gy (range 10-28 Gy) to the
median 70% isodose. The VAS score of patients with pain (median 6) dropped significantly (median 4, p = 0.002).
In 6 out of 7 patients worse sensory or motor deficit after SRS was caused by local or distant failures (diagnosed by
CT/MRI). One patient with metastatic renal cell carcinoma developed a progressive complete paraparesis one year
after the last treatment at lumbar level L3. Due to multiple surgery and radiosurgery treatments at the lumbar
region and further local progression, the exact reason remained unclear. Apart from that, no CTC grade III or
higher toxicity has been observed.
Conclusions: By applying spinal radiosurgery relevant radiation doses can be limited to small parts of the myelon.
This prevents myelopathic side effects and makes it an effective and safe treatment option for well-suited patients.
Especially for previously irradiated patients with local failure or pain salvage SRS represents a valuable treatment
option with high local control rates, low toxicity and significant pain reduction.
Background
Conventional radiotherapy (Figure 1a) is an evidence-
based treatment to control pain, neurological symptoms
and instability of spinal metastases (in general osseous
metastases, partially expanded to the spinal canal, [1] or
other spinal tumours). Rades et al. [2] described an in-
field recurrence rate up to 26% for patients with spinal
metastases treated with short course radiotherapy (1 × 8
Gy or 5 × 4 Gy). Patients treated with long course radio-
t h e r a p y( 1 0×3G y ,1 5×2 . 5G yo r2 0×2G y )s h o w e da
significantly better local control.
Stereotactic radiotherapy using either single fraction
treatments ("radiosurgery”, Figure 1b) or hypo-fractionated
approaches is an established treatment option for a variety
of malignant and non-malignant conditions including lung
cancer, metastases and CNS tumours [3-9]. The develop-
ment of modern techniques including intensity modulated
radiotherapy (IMRT), small multi-leaf collimators (MLC),
precise fixation systems and optimized dose calculations,
increase the accuracy and fidelity of radiosurgery and
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stereotactic radiotherapy is used for either small volume
lesions, small volume recurrences after prior radiotherapy
or as boost-radiotherapy in the initial management of
tumours [8,9,15].
In this regard, spinal radiosurgery (SRS) has proved to
be an important and convenient option in the treatment
of spinal metastases for properly selected patients
[16-19]. For example, SRS is not recommended in
patients with a spinal cord canal compromise > 25%,
significant or progressive neurological deficit or spine
instability [20]. Moreover the current ASTRO guidelines
for the palliative treatment of bone metastases [21]
clearly recommend conventional radiotherapy primarily
for the treatment of pain and/or prevention of the mor-
bidity caused by bone metastases.
In case of progression or local relapse spinal cord tol-
erance often limits further radiotherapy in previously
irradiated areas. For patients without surgical options
SRS offers a possibility to treat previously irradiated
regions. Stereotactic radiotherapy of the spine reduces
the radiation exposure to the spinal cord and therefore
potential neurological deficiency. The aim of this study
was to retrospectively analyse the clinical outcome for
radiosurgery of spinal metastases in previously irradiated
patients.
Methods
During a period of 4 years (2005-2009) 70 lesions were
treated with SRS (CyberKnife
®) in 54 patients (32 male,
22 female). All patients had either clinical (pain or neu-
rological) symptoms or radiological (CT/MRI) progress
i nt h ea r e ao ri nt h eb o u n d a r ya r e ao ft h ep r e v i o u s l y
irradiated fields.
The pre-irradiation treatment parameters were docu-
mented systematically (date, target volume, daily dose,
total dose, dose to the spinal cord and CT-planning
data as far as available).
For SRS treatment CyberKnife
® system and the skeletal
structure tracking software (Xsight) were used. Patients
received planning CT-scans in supine position with 1.0
mm slice thickness. MRI scans were fused with the plan-
ning CT images to augment soft tissue discrimination.
The planning target volume (PTV) was generated using
Fig. 1a
Fig. 1b
Figure 1 3-D planning in a patient with osseous metastasis in the lumbar vertebral body 5. PTV for conventional radiotherapy (Figure 1a)
included L4-L1 (® = encompassing 95%-isodose). Below (Figure 1b) salvage SRS planning in the same patient at lumbar vertebral body 5 after
conventional radiotherapy (green: 70%-isodose, yellow: 60%/50%/40%-isodose, white: 30%/20%-isodose). Abbreviation: SRS = spinal radiosurgery.
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margin. However, a certain margin resulted since the sur-
rounding isodose was calculated to extend maximal
5 mm towards the vertebral body and 0-2 mm towards
the spinal cord (Figure 1b). In some cases PET-scans
were employed to differentiate between necrotic and
relapsed tumour.
The selected SRS single fraction dose depended on
actual tumour size, the proximity of the tumour to criti-
cal structures - especially the myelon - and previous
irradiation dose and fields. The generally intended pre-
scription dose was 20 Gy calculated to the 70% isodose.
However, as mentioned above, depending on either
some risk factors or characteristics of PTV coverage this
dose prescription was adapted individually. Moreover,
the maximum dose to the spinal cord was basically
intended not to exceed 8 Gy.
For treatment delivery the patients were freely placed
on the treatment couch in the same position as during
planning CT-scan. The bone position was verified by
orthogonal X-ray images. Analgesic or sedative medica-
tion was given if required.
The radiological follow up was performed with CT or
MRI imaging at 3-months-intervals and documented pro-
spectively. Using the RECIST criteria “stable disease” and
“partial or complete remission” were defined as local con-
trol, whereas “progressive disease” was defined as local fail-
ure. Additional clinical follow up at 3-months-intervals
included neurological examination and a standardized ask-
ing procedure for pain. Pain as a main symptom was clas-
sified by using the VAS score. Apart from this prospective
evaluation of clinical outcome data the irradiation treat-
ment parameters of both conventional and stereotactic
radiotherapy were collected and analysed retrospectively.
Statistical Analysis
The Stata/IC 10.1 software (Stata Corp., College Station,
Texas, USA) was used for statistical analysis. Kaplan-
Meier method and life tables were calculated to analyse
overall survival and freedom from local failure. We used
the log-rank test to analyse the outcome for patient char-
acteristics (sex, age, Karnofsky performance status scale),
tumour characteristics (primary tumour, quantity of trea-
ted spinal lesions) and treatment-related variables (single/
total dose of conventional pre-irradiation, radiosurgery
dose, > 8-Gy-volume to the dural sac, time interval con-
ventional radiotherapy to SRS). We used the t-test to ana-
lyse VAS score as a classification for pain.
Results
70 lesions in 54 patients (32 male, 22 female) with differ-
ent primary tumour sites (sarcoma, CNS, chordoma,
renal, lung, breast, prostate, colorectal, gynaecological,
melanoma and others) were treated in 60 radiosurgery
sessions. Out of these 54 patients, 13 had progressive dis-
ease at the primary spinal/paraspinal tumour site,
whereas 41 patients suffered from metastatic disease.
Within the 41 metastatic patients most common lesions
were caused by renal cell carcinoma (n = 10; 18.5%) and
non-small-cell lung cancer (n = 7; 13%). 14 lesions in 13
patients were located intraspinal/-dural, while 56 lesions
represented osseous or paraspinal lesions. In addition, 26
patients had undergone at least secondary surgery and 30
patients had received chemotherapy before radiosurgical
treatment.
All spinal regions, but most frequently thoracic and
lumbar lesions, were affected. Detailed patient and char-
acteristics are shown in table 1.
All 70 lesions were located in conventionally pre-irra-
diated volumes. In 47 patients the prior conventional
radiotherapy (range of daily doses 1.6 - 3 Gy, 1 patient 1 ×
8 Gy) decidedly covered parts of the vertebral column/
spinal cord (but also 1 patient with whole body irradiation,
2 patients with irradiation of entire craniospinal axis, all
other patients ≥ 3 vertebral bodies), whereas 7 patients
h a db e e nt r e a t e di nt h ec o u r s eo fc u r a t i v ei n t e n d e d3 D -
plannings (mediastinal, paraaortic, paraspinal region) with
partial dose deposition to the spinal cord (single doses 1.8
- 2 Gy). Based on the available documents of prior radio-
therapy, we re-calculated the maximum total dose applied
to the myelon for the whole cohort using the linear-quad-
ratic model (a/b = 2, daily dose 2 Gy). Thus the median
re-calculated nBED Gy 2/2 to the spinal cord was 42.8 Gy
(mean 41.5 Gy, range 18 - 48.7 Gy).
32 of 54 patients suffered from significant pain before
SRS (median VAS score 6). 14 patients suffered from
complete or incomplete paresis, 12 patients suffered
from par-/hypaesthesia and 5 patients had both motor
and sensory deficits before SRS treatment.
The median time to SRS re-treatment was 15 months
(95% C.I. 14-27 months).
The median encompassing dose applied by SRS was 18
Gy (range 10-28 Gy) to the median 70%-isodose. Addi-
tionally the median tumour volume was 17.6 cc (mean
26.3 cc, range 0.2-134 cc), the median > 8-Gy-volume to
the dural sac was 0.74 cc (mean 1.4 cc, range 0-9 cc).
With the exception of two patients, who were treated
with re-radiosurgery at the same lumbar level (L3, but
contralateral vertebral body involvement) all metachro-
nously treated lesions were distant. Detailed SRS treat-
ment parameters are shown in table 2.
At a median follow up of 14.5 months (range 3-48
months) we observed 9 (12.9%) local failures (7 “in-field”
and 2 “field-margin” relapses, 10% and 2.9%, respectively)
within the 70 treated lesions. The actuarial rates of free-
dom from local failure at 6/12/18 months were 93%/88%/
85% (Figure 2). As a result in the subgroup of patients
with local failure after SRS we observed significant larger
Nikolajek et al. Radiation Oncology 2011, 6:173
http://www.ro-journal.com/content/6/1/173
Page 3 of 10tumour volumes treated by SRS (p = 0.001). Moreover, the
median time interval from conventional radiotherapy to
SRS displayed a trend to be shorter in this subgroup (p =
0.165). Detailed tumour and treatment characteristics of
patients with local failure are shown in table 3.
For the whole cohort the median overall survival after
SRS treatment were 16.2 months and 42 months after
initial radiotherapy, respectively. Patients being re-
Table 1 Patient, tumour and treatment characteristics for
all patients
Characteristic Value
Median age (years), (range) 56, (17-82)
No of patients 54
Sex
Male 32
Female 22
Karnofsky performance status scale
Median 80
Range 50-100
Spinal region/No. of treated lesions (%)
Total of lesions in 54 patients 70 (100)
Patients with 1 lesion 43
Patients with 2-6 lesions 11
Cervical 8 (11.4)
Thoracic 28 (40.0)
Lumbar 27 (38.6)
Sacral 7 (10.0)
Total of treatment sessions 60
No. of treated lesions/treatment sessions
14 2
29
32
41
Histology n (%)
Primary tumours 13 (24.1)
Sarcoma 5 (9.3)
CNS 3 (5.6)
Chordoma 3 (5.6)
Others 2 (3.7)
Metastases 41 (75.9)
Renal 10 (18.5)
Lung 7 (13)
Breast 7 (13)
Prostate 3 (5.6)
Colorectal 2 (3.7)
Gynaecological 2 (3.7)
Melanoma 1 (1.8)
Others 7 (13)
Time diagnose to SRS (years)
Median 4.6
Mean 6.7
Range 0.6-29
95% C.I. 2.4-6.4
Time RTX to SRS (months)
Median 15
Mean 42
Range 1-505
95% C.I. 13.8-26.9
Tumour volume - GTV (cc)
Median 17.6
Mean 26.3
Table 2 SRS treatment parameters
Parameter Value
Prescription dose (Gy) 70% isodose
Median 18
Mean 18.1
Range 10-28
95% C.I. 17-18
Dose maximum (GTV)
Median 25.7
Mean 26.8
Range 20-43
95% C.I. 23.9-28.6
Dose minimum (GTV)
Median 12.2
Mean 12
Range 3.8-20.3
95% C.I. 11.4-12.7
Peripheral isodose (%)
Median 70
Mean 67
Range 50-80
95% C.I. 65-70
No. of beams/site or lesion
Median 215
Mean 207
Range 64-341
95% C.I. 182-239
10 Gy irradiated volume (cc)
Median 95
Mean 120
Range 0.6-479
95% C.I. 63-132
> 8 Gy volume of spinal cord (cc)
Median 0.74
Mean 1.4
Range 0-9.3
95% C.I. 0.4-1.2
Table 1 Patient, tumour and treatment characteristics for
all patients (Continued)
Range 0.2-134
95% C.I. 12.2-26.2
Abbreviations: SRS = spinal radiosurgery; RTX = conventional radiotherapy.
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region had a significant better overall survival when
compared with patients suffering from metastatic
tumour disease (p = 0.003, Figure 3).
Among the patients with initial pain symptoms the
VAS score dropped significantly within 3 months after
the treatment (median VAS score 4, p = 0.002). After
SRS in 7 patients impairment of neurological symptoms
was found (table 4). The exact assignment of neurological
symptoms to the spinal level was not always clearly possi-
ble. One patient with renal cell carcinoma developed pro-
gressive paraparesis one year after the last treatment of a
widespread spinal metastasis at lumbar level L3 (lami-
nectomy with internal stabilization, conventional radio-
therapy, 2 times stereotactic radiosurgery at different
locations of L3, metachronous SRS at L2 and L4, surgery
for recurrence). Due to the multiple treatments and
further tumour progression in this area, the exact reason
Figure 2 Local failure-free survival after salvage spinal radiosurgery.
Table 3 Tumour and treatment characteristics for patients with local failure (n = 9)
No. Tumour
type
Location Volume
(cc)
Prescription Dose (Gy)
SRS
Isodose (%)
SRS
Time (months) RTX to
SRS
Prior RTX Dose nBED Gy
2/2
1 RCC T11 93.3 16 65 21.7 42,8
2 RCC L3 134.2 19 55 8.8 40
3 Chordoma L2 39.7 22 65 12.4 40
4 Prostate T11 89.8 18 65 2.8 45
5 Melanoma C7 17.7 17 65 4.3 33.6
6 Sarcoma L4 56.3 20 70 2 44
7 Breast L3 37.6 20 70 28.8 42.8
8 MPNST T1 26.8 14.5 70 5.8 42.8
9 RCC T9 49.9 22 70 13.9 42.8
Median - 49.9 19 65 8.8 42.8
Mean - 60.6 18.8 66 11.2 41.6
Range - 18-134 14.5-22 55-70 2-28.8 33.6-45
Abbreviations: SRS = spinal radiosurgery; RTX = conventional radiotherapy; RCC = renal cell carcinoma; MPNST = malignant peripheral nerve sheath tumour
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tion induced myelopathy has to be considered due to the
frequent radiosurgery treatments at different lumbar
levels (patient with maximum of lesions/lesion volumes
and treatment sessions in our cohort).
Apart from that, no CTC grade III or higher grade
neurological or other (necrosis, bleeding) toxicities have
been observed.
Discussion
Aim of our study was to analyse the clinical outcome of
salvage radiosurgery for spinal tumours/metastases in
previously irradiated patients in regard to efficacy (local
control, pain relief, neurological symptoms) and safety
(potential side effects). At a median follow up of 14.5
months our results in 54 patients with 70 treated lesions
by a median SRS dose of 18 Gy (range 10-28 Gy) to the
median 70%-isodose provide evidence that single-dose
application is associated with high local control rates. In
regard to symptoms of pain by using the VAS score
prospectively we observed a significant decrease of pain
in 75% of the patients. 7/54 patients developed an
impairment of neurological (2/54 sensory and 5/54
motor) deficits after SRS, among them 6 patients with
causally progressive local or distant failures.
By all means, stereotactic radiotherapy is an attractive
way to treat spinal metastases non-invasively with
encouraging results in selected patients. Although tech-
nical feasibility and growing expertise in stereotactic
treatment approaches increased accuracy and fidelity of
spinal SBRT and SRS [16,18-20,22-26] some important
challenges on this topic still remain under discussion.
The QUANTEC data review published in 2010 esti-
mated the risk for myelopathy < 1% and < 10% at 54 Gy
and 61 Gy, respectively, when conventional fractionation
(1.8-2 Gy) is used [27]. However, in the case of single-
dose or hypo-fractionated radiotherapy the maximum
spinal cord tolerance is quite more uncertain and suffi-
cient long-term-data are missing [27]. Sahgal et al [28]
calculated a dosimetric modelling by comparing SRS
parameters in not pre-irradiated patients with myelopa-
thy (n = 5) and patients without myelopathy (n = 19)
after SRS, respectively. Based on these results they
recommend a point dose threshold of 10 Gy for a single
Abbreviations: RS = radiosurgery, mets = metastases; NSCLC = non-small-cell lung cancer; RCC = 
renal call carcinoma 
Primary tumor
NSCLC mets
RCC mets
Other mets
p = 0.003
Figure 3 Overall survival from salvage spinal radiosurgery of most common tumour sites. Abbreviations: RS = radiosurgery, mets =
metastases; NSCLC = non-small-cell lung cancer; RCC = renal call carcinoma.
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et al. [29] described a partial volume tolerance to the
spinal cord of 10 Gy to 10% of the spinal cord volume
defined as 6 mm above and below the radiosurgery tar-
get. Gibbs et al. analysed 6 cases of delayed myelopathy
after SRS: A total of 1075 patients treated with radiosur-
gery were investigated and 6 patients developed a
delayed myelopathy. Specific dosimetric parameters
associated with this complication could not be identified
apart from the fact that 3 of the 6 analysed patients
received spinal cord doses above 8 Gy [26].
Nevertheless, the problem of cumulative spinal cord
tolerance for conventional radiotherapy followed by
stereotactic radiotherapy is crucial. Some recent publica-
tions also showed efficacy and safety of salvage SRS or
hypo-fractionated stereotactic radiotherapy (table 5).
Sahgal et al. [30] analysed 39 patients with 60 lesions, 37
of 60 lesions had previous irradiation. Thereby a dose of
24 Gy in three fractions to the 60%-isodose was used, the
median ≥ 8 Gy volume to the spinal cord/cauda equina
was 0.3 (range 0-28) cc and 0.3 (range 0-17) cc, respec-
tively. No myelopathy or radiculopathy occurred. For the
salvage group the 1-year progression-free probability was
96%, the median pre-irradiation total dose was 36 Gy/14
fractions. However, the median follow-up time of 7
months was rather short. There was no significant
difference in regard to clinical outcomes between pre-
viously irradiated or un-irradiated patients. By comparison
to our data with a median follow up of 14.5 months we
observed a 1-year local control rate of 88% and the median
≥ 8 Gy volume was 0.74 (range 0-9) cc in our cohort. With
regard to the pre-irradiation dose we documented a
slightly higher median nBED Gy 2/2 (42.8, range 18 - 48.7
Gy) to the spinal cord.
Choi et al. [31] confirmed safety and performance for
SRS after prior irradiation in patients with spinal metas-
tases as well. They reviewed 51 lesions in 42 patients with
a median previous spinal cord dose of 40 Gy. SRS was
delivered to a median marginal dose of 20 Gy (range 10-
30 Gy) in 1-5 fractions (median 2), according to a con-
verted median equivalent single-session tumour dose of 15
Gy (a/b = 10). With a median follow-up of 7 months the
local control rates at 6/12 months were 87%/73%. Median
single-session equivalent spinal cord maximum doses (a/b
= 3) were 10.9, 13.8, 12.5, 12.1, and 12.1 Gy for 1- to 5-ses-
sion SRS. One patient (2%) experienced Grade 4 neuro-
toxicity; a significant pain relief was observed in 65% of
the patients. Remarkably, the time to re-treatment (≤ 12
months) together with a single-session equivalent dose ≤
15 Gy was associated with a significantly higher risk for
local failure. In summary, they discuss an increased effi-
cacy of higher single-doses in case of a short period of
tumour recurrence assuming that the short time interval
between irradiation and recurrence can be interpreted as
more aggressive tumour growth behaviour. In this context
our subgroup analysis of patients with local failure
revealed a median time interval to re-treatment of 8.8
(range 2-28.8) months. However, we did not observe any
differences concerning the applied SRS doses, but our
results demonstrated significantly larger tumour volumes
in this patient group. Bearing in mind that a longer time
interval between two irradiation series to the spinal cord is
assumed to be associated with a lower risk for severe late
toxicity [27,32], both the predictive and prognostic factor
“time to re-treatment” and “tumour aggressiveness” cau-
sally increases the risk of neurological complications in
such patients.
Gerszten et al. reported the largest series of 500 cases
treated with single-session SRS (mean single dose 20,
range 12.5-25 Gy) including 344 pre-irradiated patients
[16]. At a median follow up of 21 months the long-term
local control was 88% for the most common primary
tumour sites (294 pre-irradiated and non-irradiated
patients, see table 5). Long-term pain improvement
occurred in 290 of 336 (pre-irradiated and non-irradiated)
cases. The mean < 8 Gy volume to the spinal canal was
0.6 cc for the whole cohort. Regarding the endpoints pain
and local control the authors conclude that salvage SRS
for metastases is both safe and clinically effective, espe-
cially for patients with solitary sites of spine involvement.
Table 4 Clinical (pain/neurological) outcome of all
treatment sessions
Outcome parameter Value
Total No. of treatment sessions 60
Pain
VAS Score median pre-RS (n = 60) 2
VAS Score median post-RS (n = 60) 0
p-value pre-/post-RS (n = 60) 0.07
Patients without initial pain pre-RS 26
VAS Score median pre-RS 0
Patients with pain pre-RS 32
VAS Score median pre-RS 6
VAS Score median post-RS 4
p-value pre-/post-RS 0.0056
Sensory deficit
No. of patients pre-RS 12
Sensory deficit post-RS
Better 1
Same 9
Worse 2
Motor deficit
No. of patients pre-RS 14
Motor deficit post-RS
Better 1
Same 8
Worse 5
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of spinal re-irradiation by using SBRT (5 × 6 Gy and 3
× 9 Gy prescription dose, mean total dose constraint to
the spinal cord 10 and 9 Gy, respectively) in 59 patients
[25]. At a median follow up of 17.6 months they
observed an actuarial 1-year local control rate and over-
all survival of both 76%. The CTC and McCormick neu-
rological function system were used to evaluate toxicity
and neurological status, respectively. Freedom from neu-
rologic deterioration from any cause was 92% at 1 year.
Two patients experienced mild to moderate radiation
injury (lumbar plexopathy). Based on the performed
local relapse analysis the authors conclude that initial
surgery should be considered for tumours within 5 mm
of the spinal cord.
Taken together, this data provide strong evidence that
salvage stereotactic radiotherapy in pre-irradiated
patients can be regarded as safe and effective treatment
option. Despite some limitations presented data corre-
late well with those from literature, especially regarding
the clinical outcome in terms of local control and pain
relief. Some limitations particularly result from retro-
spective analysis of radiotherapy treatment parameters
and there should be some caution in interpreting the
data. Due to the fact that previous conventional radio-
therapy often had been applied without the use of 3D
planning, exact dose distributions were not available in
all cases. Thus we did not calc u l a t eac u m u l a t i v en B E D
value for the individual patient. In this context the re-
calculated median nBED Gy 2/2 of prior conventional
radiotherapy (42.8 Gy) in our cohort was slightly higher
than reported by other groups. Moreover, reported
patient collective may be rather heterogeneous including
13 non-metastatic patients with progressive primary
tumour at the initial high-dose pre-irradiated tumour
site. Although overall survival rate in this patient sub-
group was significantly better (Figure 3) the 1-year OS
rate of 62% for the whole cohort is worse than reported
by other series. In addition, both our percentage of
intraspinal/-dural lesions (20%) in opposition to osseous
or paraspinal lesions and 14/54 patients with motor def-
icit prior to SRS have to be borne in mind.
Beside highly important challenges in technical condi-
tions accompanied by increasing accuracy and fidelity of
spinal SBRT a precise patient selection in regard to clinical
outcome is of special importance. Special criteria have to
be fulfilled like singular, small tumour volumes. In not
pre-irradiated patients the best benefit of treatment is
expected in patients with good clinical condition and
severe tumour associated pain. As mentioned above
patients with spinal cord compression more than 25%
with significant or progressive neurologic deficits or spine
instability should not be treated with SRS [16-20,25].
However, in patients compromised by previous irradiation
Table 5 Studies on spinal stereotactic re-irradiation (SBRT/SRS) after conventional radiotherapy
Author Gerszten et al. 2007 [16] Sahgal et al. 2009 [30] Choi et al. 2010 [31] Garg et al. 2011 [25]
No of patients 344/500* 39* 42 59
No. of lesions ≈344 37/60* 51 63
Tumour volume (cc)
Mean/median (range) 46/29 (0.2-264)
(n = 500*)
-/21 (0.4-177)
(n = 37)
-/10.3 (0.2-128.6) 67.1/51.2 (3.5-266)
SRS/SBRT 1 × 12.5-25 Gy (mean 20 Gy) 8-30 Gy (median 24 Gy) 10-30 Gy (median 20 Gy) 5 × 6 Gy
fractionation 1-5 fractions (median 3) 1-5 fractions (median 2) 3 × 9 Gy
Peripheral isodose 80% 60% 95%
Follow up (months) 21 (median)
(n = 500*)
7 (mean) 7 (mean) 17.6 (mean)
Local control
6 months 87%
12 months 96% (n = 31) 73% 76%
“long term” 88% (n = 294*)
Overall survival -
Median (months) 21
6 months 81%
12 months 68% 76%
24 months 45%
Previous RT dose 10 × 3 Gy or
14 × 2.5 Gy
Median 36 Gy
14 fractions
Median 40 Gy
2 Gy dose equivalent
<4 5G y
(subgroup analysis
</>35 Gy)
Abbreviations: SRS = radiosurgery; SBRT = Stereotactic body radiotherapy; *cohort included patients with/without pre-irradiation
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treatment option in some clinical constellations.
The question in how far SRS may replace in future
any conventional radiotherapy in metastatic patients
remains under debate. Patients with spinal metastases
often suffer from pain, neurological deficiency or
instability of vertebral bodies. Conventional radiotherapy
has been proven to be an effective option in the treat-
ment of spinal metastases [1]. A standard fractionation
schedule for conventional radiotherapy depends on indi-
vidual aspects of the patient like overall prognosis or
clinical symptoms. Lower daily fractions are correlated
with better remineralisation and longer pain relief than
short courses with high single doses, so patients with
oligometastases and a good prognosis may benefit from
lower daily fractions [1,23,33]. Accordingly, Rose et al
[34] described in a recent publication a higher risk of
bone fracture after first-line treating spinal metastases
located between T10 and os sacrum with high single
dose intensity-modulated radiotherapy.
In this context the current ASTRO guidelines for the
palliative treatment of bone metastases [21] clearly state
that conventional radiotherapy continues to be the main-
stay for the treatment of pain and/or prevention of the
m o r b i d i t yc a u s e db yb o n em e t a s t a s e s .T h eT a s kF o r c e
recommended that the use of SBRT/SRS in the primary
treatment setting should be limited to highly selected
patients and preferably within a prospective trial.
Conclusions
Under certain technical conditions SRS is an effective
and safe option to treat previously irradiated spinal
metastases for properly selected patients. In cases of
local failure salvage SRS reveals high local control rates
with low toxicity and significant pain reduction. Even if
SRS is not generally recommended for the primary
treatment setting of bone metastases SRS represents a
highly valuable treatment option in pre-irradiated
patients.
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